Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bridging Study of MB-102 and MediBeacon Transdermal GFR System
NCT05777174Phase 3Completed
- Sponsor
- MediBeacon
- Start
- Mar 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of relmapirazin (2 arms), sponsored by MediBeacon. Primary endpoint: Correlation of Transdermal Derived Glomerular Filtration Rate (tGFR) to the Plasma-derived Indexed Glomerular Filtration Rate (nGFR) at 24 hours. Started Mar 2023; status: completed.
02
Drugs
relmapirazin
Beyond the preview
Go deeper on NCT05777174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05777174.